Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | SLC10A2 | Q12908 | 17/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29728488 | 1.00 | NR1H4 (0.54) | NR1H4SLC10A2OPRM1OPRL1PPARG | |
| SCHEMBL23451415 | 0.91 | NR1H4 (0.47) | NR1H4SLC10A2OPRM1OPRL1PPARG | |
| SCHEMBL29728490 | 0.90 | NR1H4 (0.53) | NR1H4SLC10A2 | |
| SCHEMBL5742730 | 0.90 | NR1H4 (0.53) | NR1H4SLC10A2 | |
| SCHEMBL5421410 | 0.89 | NR1H4 (0.67) | NR1H4SLC10A2 | |
| SCHEMBL5843738 | 0.86 | NR1H4 (0.64) | NR1H4SLC10A2 | |
| SCHEMBL23451409 | 0.85 | NR1H4 (0.63) | NR1H4SLC10A2 | |
| SCHEMBL23451399 | 0.85 | NR1H4 (0.63) | NR1H4SLC10A2 | |
| SCHEMBL23451401 | 0.85 | NR1H4 (0.63) | NR1H4SLC10A2 | |
| SCHEMBL5743691 | 0.84 | NR1H4 (0.51) | NR1H4SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761018-A | Benzothiadiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2022-07-15 | — | — | CN | claimed |
| US-11225466-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2022-01-18 | — | — | US | claimed |
| US-20210171483-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | claimed |
| WO-2021110885-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | claimed |
| CN-114761018-A | Benzothiadiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11225466-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2022-01-18 | — | — | US | disclosed |
| US-20210171483-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | disclosed |
| WO-2021110885-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-1427423-B1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-7132416-B2 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | ALBIREO AB (SE) | 2005-02-17 | — | — | US | disclosed |
| EP-1427423-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022286-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171483-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 5/4885SLC10A2 2/4885OPRM1 3114/4885 |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | SLC10A2, SLC10A1, ABCB11 | NR1H4 4/4885SLC10A2 1/4885OPRM1 1622/4885 |
| US-11225466-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 5/4885SLC10A2 2/4885OPRM1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.